⌕
Repligen · RGEN · Nasdaq
Tenet 49 · Mixed
Compare
$162.18−0.37%At closeTenet 49 · Mixed
$162.18−0.60 (−0.37%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Repligen (RGEN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 16, 2026 · 03:51 ETEARNINGS EXPECTED BY FEB 22
3,054 Shares in Repligen Corporation $RGEN Bought by Ethic Inc.

Ethic Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,054 shares of …

● Seeking AlphaNov 12, 2026 · 13:19 ETEARNINGS EXPECTED BY FEB 22
Alger Mid Cap 40 ETF Q3 2026 Portfolio Review

Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from risi…

● The Motley FoolNov 5, 2026 · 11:30 ETEARNINGS EXPECTED BY FEB 22
Repligen: 3 Key Takeaways for Long-Term Investors

Repligen delivered revenue of $209 million in the third quarter. BioLife is expected to contribute $24 million in fourth-quarter revenue.…

● GlobeNewsWireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Repligen Corporation to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and …

● GlobeNewsWireOct 30, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of…

● Seeking AlphaOct 27, 2026 · 14:50 ETEARNINGS EXPECTED BY FEB 22
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript…

● MarketBeatOct 27, 2026 · 11:07 ETEARNINGS EXPECTED BY FEB 22
What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises …

● Seeking AlphaOct 27, 2026 · 10:35 ETEARNINGS EXPECTED BY FEB 22
Conestoga Small Cap Composite Q3 2026 Portfolio Activity

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, De…

● Zacks Investment ResearchOct 27, 2026 · 09:16 ETEARNINGS EXPECTED BY FEB 22
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.…

● GlobeNewsWireOct 27, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 22
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Ra…

● Defense WorldOct 15, 2026 · 03:47 ETEARNINGS EXPECTED BY FEB 22
Repligen Corporation $RGEN Stock Sold by Krilogy Financial LLC

Krilogy Financial LLC lowered its position in shares of Repligen Corporation (NASDAQ: RGEN) by 31.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund…

● Seeking AlphaOct 14, 2026 · 23:57 ET
Repligen: A Buy As Its Growth Engine Gears Up

Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration's drag is temporary, with mid-single-digit growth expected in 2026 an…

● GlobeNewsWireOct 13, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 22
Repligen to Report Third Quarter 2026 Financial Results

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026.…

● GuruFocusOct 6, 2026 · 18:25 ET
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors

On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the current price to $174.86. This movement comes amid a 52-wee…

● GlobeNewsWireOct 6, 2026 · 09:05 ETCOMPANY'S OWN WORDS
Repligen Completes Acquisition of BioLife Solutions

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has complete…

● GuruFocusOct 5, 2026 · 18:39 ET
Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100

On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. The stock has experienced a 52-week range from a low of $100.…

● MarketBeatOct 5, 2026 · 13:02 ET
BioLife Solutions Shareholders Approve Repligen Merger Agreement

BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the propo…

● Defense WorldSep 25, 2026 · 04:21 ET
Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy?

Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previou…

● Defense WorldSep 19, 2026 · 04:09 ETEARNINGS EXPECTED BY FEB 22
Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN

Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commiss…

● Business WireSep 10, 2026 · 16:12 ET
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (…

● GlobeNewsWireAug 26, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just RGEN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.